Restricted accessResearch articleFirst published online 2022-02
Microbiome Profile and Molecular Pathways Alterations in Gastrointestinal Tract by Hydrogen Sulfide-Releasing Nonsteroidal Anti-Inflammatory Drug (ATB-352): Insight into Possible Safer Polypharmacy
Nonsteroidal anti-inflammatory drugs, including ketoprofen, induce adverse effects within the gastrointestinal (GI)-tract. Hydrogen sulfide (H2S) is an antioxidative gaseous mediator contributing to GI-protection. We aimed to evaluate the GI safety of a novel H2S-releasing derivative of ketoprofen (ATB-352) versus classic ketoprofen and the molecular mechanisms of their activity after chronic treatment in experimental animal models.
Results:
Ketoprofen (10 mg/kg/day) administered intragastrically for 7 days in contrast with ATB-352 (14 mg/kg/day) reduced mucosal H2S content inducing GI damage with significantly increased injury score, altered intestinal microbiome profile, and modulation of more than 50% of 36 investigated molecular sensors (e.g., mammalian target of rapamycin or suppressor of cytokine signaling 3 [SOCS3]). Polypharmacy with aspirin (10 mg/kg/day) enhanced ketoprofen toxicity not affecting GI safety of ATB-352. Omeprazole (20 mg/kg/day) decreased ketoprofen-induced injury to the level of ATB-352 alone. Both compounds combined or not with aspirin or omeprazole maintained the ability to inhibit cyclooxygenase (COX) activity manifested by decreased prostaglandin production.
Innovation and Conclusions:
Ketoprofen-induced H2S-production decrease and intestinal microbiome profile alterations lead to GI toxicity observed on macro-/microscopic and molecular levels. Ketoprofen but not ATB-352 requires concomitant treatment with omeprazole to eliminate GI adverse effects. ATB-352 applied alone or in a polypharmacy setting with aspirin effectively inhibited COX and maintained GI safety due to H2S-release. Neither compound affected DNA oxidation in the GI mucosa, but ATB-352 had lower impact on molecular oxidative/inflammatory response pathways and intestinal microbiome. The GI safety of ATB-352 could be due to the involvement of heme oxygenase 1 and SOCS3 pathway activation. Antioxid. Redox Signal. 36, 189–210.
Get full access to this article
View all access options for this article.
References
1.
AhluwaliaA, BaatarD, JonesMK, and TarnawskiAS. Novel mechanisms and signaling pathways of esophageal ulcer healing: the role of prostaglandin EP2 receptors, cAMP, and pCREB. Am J Physiol Gastrointest Liver Physiol, 307: 602–610, 2014.
BabbinBA, LeeWY, ParkosCA, WinfreeLM, AkyildizA, PerrettiM, and NusratA. Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors. J Biol Chem, 281: 19588–19599, 2006.
4.
BinduS, MazumderS, and BandyopadhyayU. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol, 180: 114147, 2020.
5.
BlacklerR, SyerS, BollaM, OnginiE, and WallaceJL. Gastrointestinal-sparing effects of novel nsaids in rats with compromised mucosal defence. PLoS One, 7: e35196, 2012.
6.
BlacklerRW, MottaJP, MankoA, WorkentineM, BercikP, SuretteMG, and WallaceJL. Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota. Br J Pharmacol, 172: 992–1004, 2015.
7.
BlacklerRW, De PalmaG, MankoA, Da SilvaGJ, FlanniganKL, BercikP, SuretteMG, BuretAG, and WallaceJL. Deciphering the pathogenesis of NSAID enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID. Am J Physiol Gastrointest Liver Physiol, 308: 994–1003, 2015.
8.
BrancaleoneV, MitidieriE, FlowerRJ, CirinoG, and PerrettiM. Annexin a1 mediates hydrogen sulfide properties in the control of inflammation. J Pharmacol Exp Ther, 351: 96–104, 2014.
ChengHC, YangHB, ChangWL, ChenWY, YehYC, and SheuBS. Expressions of MMPs and TIMP-1 in gastric ulcers may differentiate H. pylori-infected from NSAID-related ulcers. Sci World J, 2012: 539316, DOI: 10.1100/2012/539316.
11.
ChengX, HuangF, ZhangK, YuanX, and SongC. Effects of none-steroidal anti-inflammatory and antibiotic drugs on the oral immune system and oral microbial composition in rats. Biochem Biophys Res Commun, 507: 420–425, 2018.
12.
ClementeGS, van WaardeA, AntunesIF, DömlingA, and ElsingaPH. Arginase as a potential biomarker of disease progression: a molecular imaging perspective. Int J Mol Sci, 21: 1–36, 2020.
13.
CostaSKPF, MuscaraMN, AllainT, DallazenJ, GonzagaL, BuretAG, VaughanDJ, FowlerCJ, de NucciG, and WallaceJL. Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids. Antioxid Redox Signal, 33: 1003–1009, 2020.
14.
DaiH-B, JiX, ZhuS-H, HuY-M, ZhangL-D, MiaoX-L, MaR-M, DuanM-L, and LiW-Y. Hydrogen sulphide and mild hypothermia activate the CREB signaling pathway and prevent ischemia-reperfusion injury. BMC Anesthesiol, 15: 119, 2015.
15.
EdogawaS, PetersSA, JenkinsGD, GurunathanSV, SundtWJ, JohnsonS, LennonRJ, DyerRB, CamilleriM, KashyapPC, FarrugiaG, ChenJ, SinghRJ, and GroverM. Sex differences in NSAID-induced perturbation of human intestinal barrier function and microbiota. FASEB J, 32: 6615–6625, 2018.
16.
ElbossatyWF. Dual Sword Role of Aspirin as anticancer through induced or inhibition of Autophagy through mTOR pathway. J Blood Disord Transfus, 11: 434, 2020.
17.
FernandesAD, ReidJNS, MacklaimJM, McMurroughTA, EdgellDR, and GloorGB. Unifying the analysis of high-throughput sequencing datasets: characterizing RNA-seq, 16S rRNA gene sequencing and selective growth experiments by compositional data analysis. Microbiome, 2: 15, 2014.
18.
FiorucciS and SantucciL. Hydrogen sulfide-based therapies: focus on H2S releasing NSAIDs. Inflamm Allergy Drug Targets, 10: 133–140, 2011.
19.
FuX, TanT, and LiuP. Regulation of autophagy by non-steroidal anti-inflammatory drugs in cancer. Cancer Manag Res, 12: 4595–4604, 2020.
GemiciB and WallaceJL. Anti-inflammatory and cytoprotective properties of hydrogen sulfide. Methods Enzymol,, 555: 169–193, 2015.
22.
GhoshHS, McBurneyM, and RobbinsPD. SIRT1 negatively regulates the mammalian target of rapamycin. PLoS One, 5: e9199, 2010.
23.
GrunnetM, Mau-SorensenM, and BrünnerN. Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review. Scand J Gastroenterol, 48: 899–905, 2013.
24.
GugliandoloE, FuscoR, D'AmicoR, MilitiA, OteriG, WallaceJL, Di PaolaR, and CuzzocreaS. Anti-inflammatory effect of ATB-352, a H2S-releasing ketoprofen derivative, on lipopolysaccharide-induced periodontitis in rats. Pharmacol Res, 132: 220–231, 2018.
25.
HeeneyDD, GareauMG, and MarcoML. Intestinal Lactobacillus in health and disease, a driver or just along for the ride?. Curr Opin Biotechnol, 49: 140–147, 2018.
26.
HindupurSK, GonzálezA, and HallMN. The opposing actions of target of rapamycin and AMP-Activated protein kinase in cell growth control. Cold Spring Harb Perspect Med, 5: 1–21, 2015.
27.
KissK, KissJ, RudolfE, ČervinkaM, and SzeberényiJ. Sodium salicylate inhibits NF-κB and induces apoptosis in PC12 cells. J Biochem Biophys Methods, 61: 229–240, 2004.
28.
KlionskyTS andDJ. Autophagy in health and disease: a double-edged sword. Bone, 23: 1–7, 2008.
29.
KonturekPC, KonturekK, BrzozowskiT, WojcikD, MagierowskiM, TargoszA, Krzysiek-MaczkaG, SliwowskiZ, StrzalkaM, MagierowskaK, SzczyrkU, KwiecienS, Ptak-BelowskaA, NeurathM, DieterichW, WirtzS, and ZopfY. Participation of the intestinal microbiota in the mechanism of beneficial effect of treatment with synbiotic syngut on experimental colitis under stress conditions. J Physiol Pharmacol, 71: 1–14, 2020.
30.
LasheenNN, ElayatWM, ElrefaiMFM, ZakiWS, AhmedEH, El SheikhRMN, Abo RayaDSA, and GadFRS. Possible role of garlic oil in ameliorating renal injury after liver ischemia/reperfusion in rats. J Physiol Pharmacol, 70: 765–778, 2019.
31.
LiY-J, LiJ, and DaiC. The role of intestinal microbiota and mast cell in a rat model of visceral hypersensitivity. J Neurogastroenterol Motil, 26: 529–538, 2020.
32.
LindenDR. Hydrogen sulfide signaling in the gastrointestinal tract. Antioxid Redox Signal, 20: 818–830, 2014.
33.
LombardoL, FotiM, RuggiaO, and ChiecchioA. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol, 8: 504–508, 2010.
34.
MagierowskaK, BakalarzD, WójcikD, KorbutE, DanielakA, GłowackaU, PajdoR, BuszewiczG, GinterG, SurmiakM, KwiecieńS, ChmuraA, MagierowskiM, and BrzozowskiT. Evidence for cytoprotective effect of carbon monoxide donor in the development of acute esophagitis leading to acute esophageal epithelium lesions. Cells, 9: 1203, 2020.
35.
MagierowskaK, KorbutE, Hubalewska-MazgajM, SurmiakM, ChmuraA, BakalarzD, BuszewiczG, WójcikD, ŚliwowskiZ, GinterG, GromowskiT, KwiecieńS, BrzozowskiT, and MagierowskiM. Oxidative gastric mucosal damage induced by ischemia/reperfusion and the mechanisms of its prevention by carbon monoxide-releasing tricarbonyldichlororuthenium (II) dimer. Free Radic Biol Med, 145: 198–208, 2019.
36.
MagierowskiM, MagierowskaK, Hubalewska-MazgajM, SliwowskiZ, PajdoR, GinterG, KwiecienS, BrzozowskiT, NagaharaN, and WrobelM. Exogenous and endogenous hydrogen sulfide protects gastric mucosa against the formation and time-dependent development of ischemia/reperfusion-induced acute lesions progressing into deeper ulcerations. Molecules, 22: 295, 2017.
37.
MagierowskiM, MagierowskaK, SurmiakM, Hubalewska-MazgajM, KwiecienS, WallaceJL, and BrzozowskiT. The effect of hydrogen sulfide-releasing naproxen (ATB-346) versus naproxen on formation of stress-induced gastric lesions, the regulation of systemic inflammation, hypoxia and alterations in gastric microcirculation. J Physiol Pharmacol, 68: 749–756, 2017.
38.
MagierowskiM, MagierowskaK, SzmydJ, SurmiakM, SliwowskiZ, KwiecienS, and BrzozowskiT. Hydrogen sulfide and carbon monoxide protect gastric mucosa compromised by mild stress against alendronate injury. Dig Dis Sci, 61: 3176–3189, 2016.
39.
MangifestaM, MancabelliL, MilaniC, GaianiF, de'AngelisN, de'AngelisGL, van SinderenD, VenturaM, and TurroniF. Mucosal microbiota of intestinal polyps reveals putative biomarkers of colorectal cancer. Sci Rep, 8: 1–9, 2018.
40.
MarliczW, ŁoniewskiI, GrimesDS, and QuigleyEM. Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small Intestine. Mayo Clin Proc, 89: 1699–1709, 2014.
41.
MartinGR, PerrettiM, FlowerRJ, and WallaceJL. Annexin-1 modulates repair of gastric mucosal injury. Am J Physiol Gastrointest Liver Physiol, 294: G764-9, 2008.
42.
MasedaD and RicciottiE. NSAID–gut microbiota interactions. Front Pharmacol, 11: 1153, 2020.
43.
MatsuiH, ShimokawaO, KanekoT, NaganoY, RaiK, and HyodoI. The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine. J Clin Biochem Nutr, 48: 107–111, 2011.
44.
MontenegroL, LosurdoG, LicinioR, ZamparellaM, GiorgioF, IerardiE, LeoA, and PrincipiM. Non steroidal anti-inflammatory drug induced damage on lower gastro-intestinal tract: is there an involvement of microbiota?. Curr Drug Saf, 9: 196–204, 2014.
45.
OtaniK, TanigawaT, WatanabeT, ShimadaS, NadataniY, NagamiY, TanakaF, KamataN, YamagamiH, ShibaM, TominagaK, FujiwaraY, and ArakawaT. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage. digestion, 95: 22–28, 2017.
46.
QuastC, PruesseE, YilmazP, GerkenJ, SchweerT, YarzaP, PepliesJ, and GlöcknerFO. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res, 41: D590, 2013.
47.
Rajilić-StojanovićM, BiagiE, HeiligHGHJ, KajanderK, KekkonenRA, TimsS, and De VosWM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology, 141: 1792–1801, 2011.
48.
RogersMAM and AronoffDM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect, 22: 178.e1–178.e9, 2016.
49.
RudnickDA, PerlmutterDH, and MugliaLJ. Prostaglandins are required for CREB activation and cellular proliferation during liver regeneration. Proc Natl Acad Sci U S A, 98: 8885–8890, 2001.
50.
RussellRI. Non-steroidal anti-inflammatory drugs and gastrointestinal damage—problems and solutions. Postgrad Med J, 77: 82–88, 2001.
51.
SampsonLL, DavisAK, GroggMW, and ZhengY. mTOR disruption causes intestinal epithelial cell defects and intestinal atrophy postinjury in mice. FASEB J, 30: 1263–1275, 2016.
52.
SchmittgenTD and LivakKJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc, 3: 1101–1108, 2008.
53.
ShenF, ZhaoCS, ShenMF, WangZ, and ChenG. The role of hydrogen sulfide in gastric mucosal damage. Med Gas Res, 9: 88–92, 2019.
54.
Da SilvaEAW, Da SilvaNMJW, RodriguesRR, AdadSJ, De Lima PereiraSA, RibeiroBM, MendonçaMS, HelmoFR, RodriguesV, and RodriguesDBR. Arginase-1 and treg profile appear to modulate inflammatory process in patients with chronic gastritis: IL-33 may be the alarm cytokine in H. pylori-positive patients. Mediators Inflamm, 2019: 2536781, 2019.
55.
SinghS and LinH. Hydrogen sulfide in physiology and diseases of the digestive tract. Microorganisms, 3: 866–889, 2015.
56.
SomasundaramS, RafiS, HayllarJ, SigthorssonG, JacobM, PriceAB, MacphersonA, MahmodT, ScottD, WrigglesworthJM, and BjarnasonI. Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID induced injury to the rat intestine. Gut, 41: 344–353, 1997.
57.
StarkLA, ReidK, SansomOJ, DinFV, GuichardS, MayerI, JodrellDI, ClarkeAR, and DunlopMG. Aspirin activates the NF-κB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis, 28: 968–976, 2007.
58.
SunH, YangJ, ShiY, WangY, LiC, and ZhuM. Hydrogen sulfide in the nucleus tractus solitarii regulates gastric acid secretion in rats. J Physiol Pharmacol, 71: 1–5, 2020.
59.
SunziniF, De StefanoS, ChimentiMS, and MelinoS. Hydrogen sulfide as potential regulatory gasotransmitter in arthritic diseases. Int J Mol Sci, 21: 1180, 2020.
60.
SyerSD, BlacklerRW, MartinR, de PalmaG, RossiL, VerduE, BercikP, SuretteMG, AucouturierA, LangellaP, and WallaceJL. NSAID enteropathy and bacteria: a complicated relationship. J Gastroenterol, 50: 387–393, 2015.
61.
SyggelosSA, GiannopoulouE, GouvousisPA, AndonopoulosAP, AletrasAJ, and PanagiotopoulosE. In vitro effects of non-steroidal anti-inflammatory drugs on cytokine, prostanoid and matrix metalloproteinase production by interface membranes from loose hip or knee endoprostheses. Osteoarthr Cartil, 15: 531–542, 2007.
62.
ThibaultMP, Tremblay É, WallaceJL, and BeaulieuJF. Effect of ketoprofen and atb-352 on the immature human intestine: identification of responders and non-responders. J Pediatr Gastroenterol Nutr, 68: 623–629, 2019.
WallaceJL, CaliendoG, SantagadaV, and CirinoG. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol, 159: 1236–1246, 2010.
65.
WallaceJL, IanaroA, and de NucciG. Gaseous mediators in gastrointestinal mucosal defense and injury. Dig Dis Sci, 62: 2223–2230, 2017.
66.
WallaceJL, NagyP, FeenerTD, AllainT, DitróiT, VaughanDJ, MuscaraMN, de NucciG, and BuretAG. A proof-of-concept, phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide-releasing anti-inflammatory drug. Br J Pharmacol, 177: 769–777, 2020.
67.
WallaceJL, de NucciG, and SulaievaO. Toward more GI-friendly anti-inflammatory medications. Curr Treat Options Gastroenterol, 13: 377–385, 2015.
68.
WallaceJL, SyerS, DenouE, De PalmaG, VongL, McKnightW, JuryJ, BollaM, BercikP, CollinsSM, VerduE, and OnginiE. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology, 141: 1314.e5–1322.e5, 2011.
69.
WallaceJL and WangR. Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nat Rev Drug Discov, 14: 329–345, 2015.
70.
WatanabeT, FujiwaraY, and ChanFKL. Current knowledge on non-steroidal anti-inflammatory drug-induced small-bowel damage: a comprehensive review. J Gastroenterol, 55: 481–495, 2020.
71.
WhitemanM, Le TrionnaireSL, ChopraM, FoxB, and WhatmoreJ. Emerging role of hydrogen sulfide in health and disease: critical appraisal of biomarkers and pharmacological tools. Clin Sci, 121: 459–488, 2011.
72.
WuYC, WangXJ, YuL, ChanFKL, ChengASL, YuJ, SungJJY, WuWKK, and ChoCH. Hydrogen sulfide lowers proliferation and induces protective autophagy in colon epithelial cells. PLoS One, 7: e37572, 2012.
73.
XiaoX, NakatsuG, JinY, WongS, YuJ, and LauJYW. Gut microbiota mediates protection against enteropathy induced by indomethacin. Sci Rep, 7: 1–11, 2017.
74.
YuL, WangL, YiH, and WuX. Beneficial effects of LRP6-CRISPR on prevention of alcohol-related liver injury surpassed fecal microbiota transplant in a rat model. Gut Microbes, 11: 1015–1029, 2020.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
